Swiss pharmaceutical giant Roche ($RHHBY) has agreed to acquire U.S. biotech company 89bio ($ETNB) for a price of up to $3.5 ...

We recently published 10 Stocks Stole the Show, 5 Hit Historic Highs. 89bio Inc. (NASDAQ:ETNB) is one of the best performers ...

Roche acquires 89bio for up to $3.5B, betting on pegozafermin for MASH. Click here to read the latest analysis on ETNB and ...

Small-cap benchmark Russell 2000 ETF hits record high after Fed cuts rates, hinting at more cuts. Small caps rally 43% since ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of 89bio, Inc. (NASDAQ: ETNB) to Roche is fair to 89bio shareholders. Under the terms of the proposed transaction, ...

The deal seeks to strengthen the drugmaker’s pipeline by adding an experimental treatment for a liver disease linked to ...

What’s Driving 89bio These Days? Sometimes, a stock’s movements can catch investors off guard and spark questions about what’s really going on beneath the surface. That seems to be the case with 89bio ...

Roche is set to acquire 89bio for $3.5B, adding late-stage MASH drug pegozafermin to its cardiovascular, renal, and metabolic pipeline.

Inc. (NASDAQ:ETNB) is one of the Top 10 Stocks Under $10 That Could Triple. On September 4, H.C. Wainwright started coverage ...

California, USA-based liver specialist 89bio saw its shares rocket more than 83% to $14.83 in pre-market activity on the news ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is 89BIO (ETNB) one of those stocks right now? Let's take a ...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of 89bio, Inc. (NasdaqGM: ETNB) to Roche Holding ...